Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis

ConditionsSporadic Inclusion Body Myositis (sIBM)Idiopathic Inflammatory Myopathies

Trial statusRecruiting

Trial phaseEarly Phase 1

Trial typeInterventional

Biological sexAll

Age45-75

SponsorAustin Neuromuscular Center

About this trial

To evaluate the efficacy of Pozelimab/Cemdisiran combination therapy in patients with sIBM

Eligibility criteria

Qualifiers

1. Age ≥45 years to 75 years of age 2. Diagnosed with sIBM based on the ENMC IBM Research Diagnostic Criteria 3. Willing and able to comply with clinic visits and study-related procedures. 4. Provide informed consent signed by the study patient or legally acceptable representative.

Intravaginal

Transdermal

Oral

Disqualifiers

1. Other neurological conditions (e.g., hemiplegia post-stroke, Parkinson's Disease) or musculoskeletal conditions (e.g., severe osteoarthritis) causing mobility impairment.

Trial design

Treatments tested in this trial

Pozelimab/Cemdisiran

Treatment groups

10 Participants

are divided into 1 treatment group

Sponsors and collaborators

Austin Neuromuscular Center

Lead sponsor

Regeneron Pharmaceuticals

Collaborator

Source ClinicalTrials.gov